Investments
25Portfolio Exits
10Partners & Customers
10Service Providers
1About Novo Nordisk
Novo Nordisk (CPH: NOVO-B) is a healthcare company that specializes in diabetes care. It also operates in hemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). The company was founded in 1989 and is based in Bagsvaerd, Denmark.
Want to inform investors similar to Novo Nordisk about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Expert Collections containing Novo Nordisk
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Novo Nordisk in 5 Expert Collections, including Synthetic Biology.
Synthetic Biology
382 items
Conference Exhibitors
5,302 items
Diabetes
1,903 items
Medical Devices
3,501 items
https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.
Biopharma Tech
260 items
Research containing Novo Nordisk
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Novo Nordisk in 5 CB Insights research briefs, most recently on Nov 19, 2022.
Nov 19, 2022
State of Enterprise Blockchain 2022
Mar 26, 2020
40+ ‘Breakthrough’ Medical Device StartupsLatest Novo Nordisk News
Feb 2, 2023
(marketscreener.com) Already positive, the research from Deutsche Bank and its analyst Emmanuel Papadakis still consider the stock as a Buy opportunity. The target price continues to be set at DKK 1200.https://www.marketscreener.com/quote/stock/NOVO-NORDISK-A-S-1412980/news/NOVO-NORDISK-Deutsche-Bank-gives-a-Buy-rating-42876901/?utm_medium=RSS&utm_content=20230202
Novo Nordisk Investments
25 Investments
Novo Nordisk has made 25 investments. Their latest investment was in Amalgam Rx as part of their Corporate Minority on December 12, 2022.
Novo Nordisk Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
12/19/2022 | Corporate Minority | Amalgam Rx | $17.37M | Yes | 2 | |
2/18/2022 | Series C | Beta Bionics | $57M | No | 4 | |
3/16/2021 | Series D | Glooko | $30M | Yes | 14 | |
2/10/2021 | Unattributed | |||||
10/29/2019 | Series A |
Date | 12/19/2022 | 2/18/2022 | 3/16/2021 | 2/10/2021 | 10/29/2019 |
|---|---|---|---|---|---|
Round | Corporate Minority | Series C | Series D | Unattributed | Series A |
Company | Amalgam Rx | Beta Bionics | Glooko | ||
Amount | $17.37M | $57M | $30M | ||
New? | Yes | No | Yes | ||
Co-Investors | |||||
Sources | 2 | 4 | 14 |
Novo Nordisk Portfolio Exits
10 Portfolio Exits
Novo Nordisk has 10 portfolio exits. Their latest portfolio exit was Disc Medicine on December 29, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
12/29/2022 | Reverse Merger | 5 | |||
7/17/2020 | IPO | Public | 3 | ||
8/1/2019 | IPO | Public | 3 | ||
Date | 12/29/2022 | 7/17/2020 | 8/1/2019 | ||
|---|---|---|---|---|---|
Exit | Reverse Merger | IPO | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | |||
Sources | 5 | 3 | 3 |
Novo Nordisk Acquisitions
12 Acquisitions
Novo Nordisk acquired 12 companies. Their latest acquisition was Forma Therapeutics on September 01, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
9/1/2022 | Series D | $129.5M | Acq - Pending | 3 | ||
12/28/2021 | Series C | $123.8M | Take Private | 7 | ||
7/12/2021 | Acquired | 1 | ||||
12/8/2020 | ||||||
6/11/2020 | Series B |
Date | 9/1/2022 | 12/28/2021 | 7/12/2021 | 12/8/2020 | 6/11/2020 |
|---|---|---|---|---|---|
Investment Stage | Series D | Series C | Series B | ||
Companies | |||||
Valuation | |||||
Total Funding | $129.5M | $123.8M | |||
Note | Acq - Pending | Take Private | Acquired | ||
Sources | 3 | 7 | 1 |
Novo Nordisk Partners & Customers
10 Partners and customers
Novo Nordisk has 10 strategic partners and customers. Novo Nordisk recently partnered with Howwe on January 1, 2023.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
1/25/2023 | Licensor | Howwe | Novo Nordisk Enters a New License Agreement for the Enterprise Execution Software Howwe® `` We are pleased to continue the partnership with Howwe Technologies , '' said Niels Abel Bonde , General Manager & VP of Novo Nordisk . | 2 | |
12/9/2022 | Partner | Rwanda | A partnership between Babyl -- a subsidiary of Babylon -- and Novo Nordisk will help contribute to the expansion of diabetes awareness and care in Rwanda through community engagement and skills building using digital technology . | 1 | |
11/21/2022 | Licensor | Ireland | Prothena Corporation plc 's pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis , ATTR amyloidosis , Alzheimer 's disease , Parkinson 's disease and a number of other neurodegenerative diseases . | 2 | |
11/17/2022 | Partner | ||||
10/26/2022 | Partner |
Date | 1/25/2023 | 12/9/2022 | 11/21/2022 | 11/17/2022 | 10/26/2022 |
|---|---|---|---|---|---|
Type | Licensor | Partner | Licensor | Partner | Partner |
Business Partner | Howwe | ||||
Country | Rwanda | Ireland | |||
News Snippet | Novo Nordisk Enters a New License Agreement for the Enterprise Execution Software Howwe® `` We are pleased to continue the partnership with Howwe Technologies , '' said Niels Abel Bonde , General Manager & VP of Novo Nordisk . | A partnership between Babyl -- a subsidiary of Babylon -- and Novo Nordisk will help contribute to the expansion of diabetes awareness and care in Rwanda through community engagement and skills building using digital technology . | Prothena Corporation plc 's pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis , ATTR amyloidosis , Alzheimer 's disease , Parkinson 's disease and a number of other neurodegenerative diseases . | ||
Sources | 2 | 1 | 2 |
Novo Nordisk Service Providers
1 Service Provider
Novo Nordisk has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
|---|---|---|---|
Merger | Investment Bank | Financial Advisor |
Service Provider | |
|---|---|
Associated Rounds | Merger |
Provider Type | Investment Bank |
Service Type | Financial Advisor |
Partnership data by VentureSource
Novo Nordisk Team
28 Team Members
Novo Nordisk has 28 team members, including current Chief Executive Officer, President, Lars Rebien Soerensen.
Name | Work History | Title | Status |
|---|---|---|---|
Lars Rebien Soerensen | Chief Executive Officer, President | Current | |
Name | Lars Rebien Soerensen | ||||
|---|---|---|---|---|---|
Work History | |||||
Title | Chief Executive Officer, President | ||||
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.